These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1703352)

  • 21. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation.
    Wissing KM; Abramowicz D; Weekers L; Budde K; Rath T; Witzke O; Broeders N; Kianda M; Kuypers DRJ
    Am J Transplant; 2018 Jul; 18(7):1726-1734. PubMed ID: 29337426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: A Collaborative Transplant Study Report.
    Süsal C; Döhler B
    Am J Transplant; 2019 Oct; 19(10):2805-2813. PubMed ID: 30859672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of allergy to tacrolimus in kidney transplant candidates and recipients with a history of macrolide antibiotic allergy.
    Trofe-Clark J; Doshi M; Fadugba O; Lim MA
    Am J Transplant; 2018 Jul; 18(7):1831-1832. PubMed ID: 29673079
    [No Abstract]   [Full Text] [Related]  

  • 25. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.
    Rodríguez-Perálvarez M; Guerrero-Misas M; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011639. PubMed ID: 28362060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.
    Dugast E; Soulillou JP; Foucher Y; Papuchon E; Guerif P; Paul C; Riochet D; Chesneau M; Cesbron A; Renaudin K; Dantal J; Giral M; Brouard S
    Am J Transplant; 2016 Nov; 16(11):3255-3261. PubMed ID: 27367750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506.
    Watanabe K; Yuge K; Sato K; Sonoda K; Masaki Y; Maruyama S; Okubo M; Obata F; Otani F; Kaneko T
    Transplant Proc; 1991 Feb; 23(1 Pt 1):568-72. PubMed ID: 1703706
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients.
    Braun F; Schütz E; Peters B; Talaulicar R; Grupp C; Undre N; Schäfer A; Armstrong VW; Oellerich M; Ringe B
    Transplant Proc; 2001 May; 33(3):2127-8. PubMed ID: 11377473
    [No Abstract]   [Full Text] [Related]  

  • 29. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression.
    Burke GW; Alejandro R; Ciancio G; Nery J; Roth D; Shapiro R; Scantlebury V; Skyler JS; Ricordi C; Tzakis A
    Transplant Proc; 1995 Dec; 27(6):3123-4. PubMed ID: 8539874
    [No Abstract]   [Full Text] [Related]  

  • 30. Renal transplantation--demystifying the process.
    Cross J
    CANNT J; 2003; 13(3):40-59; quiz 48-9. PubMed ID: 14596198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The question of FK 506 nephrotoxicity after liver transplantation.
    McCauley J; Takaya S; Fung J; Tzakis A; Abu-Elmagd K; Jain A; Todo S; Starzl TE
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1444-7. PubMed ID: 1703344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
    Steurer W; Malaise J; Mark W; Koenigsrainer A; Margreiter R;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii54-62. PubMed ID: 15814551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
    Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
    Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver, kidney, and thoracic organ transplantation under FK 506.
    Todo S; Fung JJ; Starzl TE; Tzakis A; Demetris AJ; Kormos R; Jain A; Alessiani M; Takaya S; Shapiro R
    Ann Surg; 1990 Sep; 212(3):295-305; discussion 306-7. PubMed ID: 1697743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early steroid withdrawal results in improved patient and graft survival and lower risk of post-transplant cardiovascular risk profiles: A single-center 10-year experience.
    Lopez-Soler RI; Chan R; Martinolich J; Park L; Ata A; Chandolias N; Conti DJ
    Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27888534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
    Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
    Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation.
    Shapiro R; Ellis D; Tan HP; Moritz ML; Basu A; Vats AN; Kayler LK; Erkan E; McFeaters CG; James G; Grosso MJ; Zeevi A; Gray EA; Marcos A; Starzl TE
    Am J Transplant; 2007 Dec; 7(12):2736-8. PubMed ID: 17908272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients.
    Cena T; Musetti C; Quaglia M; Magnani C; Stratta P; Bagnardi V; Cantaluppi V
    Transpl Int; 2016 Oct; 29(10):1085-93. PubMed ID: 27343849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.
    Seibert SR; Schladt DP; Wu B; Guan W; Dorr C; Remmel RP; Matas AJ; Mannon RB; Israni AK; Oetting WS; Jacobson PA
    Clin Transplant; 2018 Dec; 32(12):e13424. PubMed ID: 30318646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.